Incyte Corp (INCY)
Sector: Industrials
Industry: Services-Commercial Physical & Biological Research
Country: United States
Exchange: NASDAQ
Market cap: $25.87B
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Latest financial period: March 31, 2026
Filed with the SEC: April 28, 2026
Estimated earnings date: October 27, 2026
Not currently ranked. Cannot calculate: FCF yield
Profit Not currently ranked
| | Mar 26 | Dec 25 | Sep 25 | Jun 25 |
|---|
| ROIC | | | | |
Growth Not currently ranked
Payout Not currently ranked
Safety Not currently ranked
Price Not currently ranked
